Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment algorithms in stage IV melanoma.

American journal of therapeutics - 1 Jan 2000

Espinosa Enrique, Grob Jean-Jacques, Dummer Reinhard, Rutkowski Piotr, Robert Caroline, Gogas Helen, Kefford Richard, Eggermont Alexander M M, Martin Algarra Salvador, Hauschild Axel, Schadendorf Dirk

Abstract excerpt

The molecular classification of melanoma and the advent of new drugs are changing the paradigm of therapy for advanced melanoma. A review of the recent key studies was performed, followed by a discussion in an expert forum. The aim of this review was to generate a therapeutic algorithm for stage IV melanoma. Tumor genotyping for BRAF and/or KIT should be performed before selection of therapy. For most...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Design
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Staging

Share to Skin Neoplasms

Share to Survival Rate

Share to Clinical Trials as Topic

Share to Algorithms

Share to Antineoplastic Agents

Source

Identifiers

PMID: 24413374
DOI: 10.1097/MJT.0b013e31829e885c

Genes

BRAF
KIT
CTLA4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment algorithms in stage IV melanoma.PMID 24413374Read ↗

Melanoma: diagnosis, staging, and treatment. Consensus group recommendations.Semantic proximity Read ↗

Toward a molecular classification of melanoma.Semantic proximity Read ↗

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.Semantic proximity Read ↗

Frontline approach to metastatic BRAF-mutant melanoma diagnosis, molecular evaluation, and treatment choice.Semantic proximity Read ↗

BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel.Semantic proximity Read ↗

Immunotherapy and Targeted Therapy in Patients With Advanced Melanoma and the V600 BRAF Mutation: Which One First?Semantic proximity Read ↗

Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Semantic proximity Read ↗

The Current State of Molecular Testing in the BRAF-Mutated Melanoma LandscapeSemantic proximity Read ↗

Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience.Semantic proximity Read ↗

Update on the targeted therapy of melanoma.Semantic proximity Read ↗

Vemurafenib therapy for stage IV melanoma with V600G-mutation.Semantic proximity Read ↗

BRAF targeted therapy changes the treatment paradigm in melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.